All In Biotech

Drug Trial Radar · NCT05188989

Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction.

A Multi-Center ,Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of TPN171H in Patients With Erectile Dysfunction

Last checked: Nov 20, 2026Latest source record: Mar 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 765 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

765

Actual

Start

Dec 31, 2021

Primary completion

Feb 14, 2023

Study completion Feb 14, 2023

Sponsor

Lead sponsor
Vigonvita Life SciencesIndustry
Sponsor type
Industry
First posted
Jan 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double blind, placebo-controlled, parallel design study to evaluate the efficacy and safety of TPN171H in men with erectile dysfunction.

Conditions

  • Erectile Dysfunction

Interventions

  • TPN171H 2.5mg groupDrug

    TPN171H 2.5mg taken orally on demand 0.5-4 hour prior to sexual intercourse

  • TPN171H 5mg groupDrug

    TPN171H 5mg taken orally on demand 0.5-4 hour prior to sexual intercourse

  • TPN171H 10mg groupDrug

    TPN171H 10mg taken orally on demand 0.5-4 hour prior to sexual intercourse

  • Placebo groupDrug

    Placebo taken orally on demand 0.5-4 hour prior to sexual intercourse

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) at Week 12Time frame: baseline and 12 weeks
  2. Change From Baseline in Question 2 of the Patient Sexual Encounter Profile (SEP) Diary at Week 12 in Percentage of Yes ResponsesTime frame: baseline and 12 weeks
  3. Change From Baseline in Question 3 of the Patient Sexual Encounter Profile (SEP) Diary at Week 12 in Percentage of Yes ResponsesTime frame: baseline and 12 weeks

Locations

49 sites in 1 country. Site status is shown where the registry gives one.

  • The Second People's Hospital of Hefei

    Hefei, Anhui, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The first affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Peking University Shougang Hospital

    Beijing, Beijing Municipality, China

  • Xiyuan Hospital china Academy of chinese Medical Sciences

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China

  • Southern Medical University Nanfang Hospital

    Guangzhou, Guangdong, China

  • The Fifth Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Shenzhen University General Hospital

    Shenzhen, Guangdong, China

  • Songgang People's Hospital

    Shenzhen, Guangdong, China

  • The Eighth Affiliated Hospital Sun Yat-sen University

    Shenzhen, Guangdong, China

  • Zhuhai People's Hospital

    Zhuhai, Guangdong, China

  • Liuzhou peopleˊs Hospital

    Liuzhou, Guangxi, China

  • The Second Nanning People's Hospital

    Nanning, Guangxi, China

  • The First Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • People's Hospital of zhengzhou

    Zhengzhou, Henan, China

  • Henan Provincial People's Hospital

    Zhenzhou, Henan, China

  • Tongji Medical College of HUST

    Wuhan, Hubei, China

  • The Central Hospital of Wuhan

    Wuhan, Hubei, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Jiangsu Provincial Hospital of Chinese Medicine

    Nanjing, Jiangsu, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • Nanchang reproductive hospital

    Nanchang, Jiangxi, China

  • First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The Affiliated Hospital to Changchun University of Traditional Medicine

    Changchun, Jilin, China

  • The Frist Hospital of Jilin University

    Changchun, Jilin, China

  • The First Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • The Second Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, China

  • Qinghai university affiliated hospital

    Xining, Qinghai, China

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.